<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>RepathaÂ® (evolocumab) - Comprehensive Profile | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        /* Custom animations matching your style */
        @keyframes fadeInRow {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        @keyframes pulse {
            0%, 100% { opacity: 0.5; transform: scale(0.95); }
            50% { opacity: 0.8; transform: scale(1.1); }
        }
        @keyframes slideIn {
            from { opacity: 0; transform: translateX(-10px); }
            to { opacity: 1; transform: translateX(0); }
        }
        .animate-fade-in-row { animation: fadeInRow 0.3s ease forwards; }
        .animate-pulse-glow { animation: pulse 3s ease-in-out infinite; }
        .animate-slide-in { animation: slideIn 0.6s ease-out forwards; }
        
        /* Staggered animations */
        .stagger-1 { animation-delay: 0.1s; }
        .stagger-2 { animation-delay: 0.2s; }
        .stagger-3 { animation-delay: 0.3s; }
        .stagger-4 { animation-delay: 0.4s; }
        .stagger-5 { animation-delay: 0.5s; }
        
        /* Custom scrollbar */
        ::-webkit-scrollbar { width: 8px; height: 8px; }
        ::-webkit-scrollbar-track { @apply bg-gray-100 dark:bg-gray-800 rounded; }
        ::-webkit-scrollbar-thumb { @apply bg-gray-400 dark:bg-gray-600 rounded hover:bg-gray-500 dark:hover:bg-gray-500; }
        
        /* Glass effect */
        .glass {
            background: rgba(255, 255, 255, 0.75);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
        }
        .dark .glass {
            background: rgba(17, 24, 39, 0.75);
        }
    </style>
</head>
<body class="bg-gray-50 dark:bg-gray-900 transition-all duration-300">
    <!-- Fixed Header - Matching your Leaf Intelligence design -->
    <header class="fixed top-0 left-0 right-0 z-50 glass border-b border-gray-200 dark:border-gray-700 shadow-lg">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex justify-between items-center py-4">
                <!-- Logo -->
                <div class="flex items-center space-x-3">
                    <div class="relative">
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-12 w-12 relative z-10">
                        <div class="absolute inset-0 bg-gradient-to-r from-green-400 to-cyan-400 opacity-20 blur-xl animate-pulse-glow"></div>
                    </div>
                    <div>
                        <div class="text-xl font-light bg-gradient-to-r from-green-600 to-cyan-600 dark:from-green-400 dark:to-cyan-400 bg-clip-text text-transparent">
                            Leaf Intelligence
                        </div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 font-light">
                            Cholesterol Therapies Analysis
                        </div>
                    </div>
                </div>

                <!-- Navigation -->
                <nav class="hidden md:flex items-center space-x-1 bg-gray-100/50 dark:bg-gray-800/50 p-1.5 rounded-lg backdrop-blur-sm">
                    <a href="index.html" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Overview
                    </a>
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 bg-white dark:bg-gray-700 text-indigo-600 dark:text-indigo-400 shadow-md active">
                        Drug Profile
                    </button>
                    <a href="index.html#comparison" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Comparison
                    </a>
                </nav>

                <!-- Theme Toggle -->
                <button onclick="toggleTheme()" class="relative w-14 h-7 rounded-full bg-gray-200 dark:bg-gray-700 transition-all duration-300 shadow-inner hover:shadow-md">
                    <div class="absolute top-0.5 left-0.5 w-6 h-6 rounded-full bg-white dark:bg-gray-900 shadow-lg transform transition-transform duration-300 dark:translate-x-7 flex items-center justify-center">
                        <svg class="w-4 h-4 text-yellow-500 dark:hidden" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M12 7a5 5 0 100 10 5 5 0 000-10z"/>
                        </svg>
                        <svg class="w-4 h-4 text-indigo-400 hidden dark:block" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/>
                        </svg>
                    </div>
                </button>
            </div>
        </div>
    </header>

    <!-- Main Container with padding for fixed header -->
    <div class="pt-20 min-h-screen">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
            
            <!-- Hero Section -->
            <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-col md:flex-row justify-between items-start md:items-center gap-4">
                    <div>
                        <h1 class="text-4xl font-light mb-2 text-gray-900 dark:text-white">
                            RepathaÂ® <span class="text-2xl text-gray-600 dark:text-gray-400">(evolocumab)</span>
                        </h1>
                        <p class="text-lg text-gray-600 dark:text-gray-400">
                            PCSK9 Monoclonal Antibody â€¢ Amgen
                        </p>
                    </div>
                    <div class="flex flex-wrap gap-2">
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-green-500 to-emerald-500 text-white">
                            âœ“ FDA/EMA Approved
                        </span>
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-indigo-500 to-purple-500 text-white">
                            ðŸŽ¯ CV Outcomes Proven
                        </span>
                    </div>
                </div>
            </div>

            <!-- Tab Navigation -->
            <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-wrap gap-1 p-2">
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-indigo-600 text-white" onclick="showTab('overview', event)">
                        Overview
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('mechanism', event)">
                        Mechanism
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('regulatory', event)">
                        Regulatory
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('clinical', event)">
                        Clinical Trials
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('safety', event)">
                        Safety
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('market', event)">
                        Commercial
                    </button>
                </div>
            </div>

            <!-- Overview Tab -->
            <div class="tab-content active" id="overview">
                <!-- Key Metrics Grid -->
                <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-4 gap-6 mb-8">
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-indigo-600 to-purple-600 bg-clip-text text-transparent mb-2">
                            60%
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">LDL-C Reduction</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">FOURIER: 59%</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-green-600 to-emerald-600 bg-clip-text text-transparent mb-2">
                            15%
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">MACE Reduction</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">HR 0.85</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-amber-600 to-orange-600 bg-clip-text text-transparent mb-2">
                            Q2W
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Dosing Frequency</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">or Monthly</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                        <div class="text-3xl font-bold bg-gradient-to-r from-purple-600 to-pink-600 bg-clip-text text-transparent mb-2">
                            $5,850
                        </div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Annual Cost</div>
                        <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">60% price cut from launch</div>
                    </div>
                </div>

                <!-- Patient Populations -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Approved Indications</h3>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Adults</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li class="flex items-start">
                                    <span class="text-green-500 mr-2 mt-1">â€¢</span>
                                    Heterozygous Familial Hypercholesterolemia (HeFH)
                                </li>
                                <li class="flex items-start">
                                    <span class="text-green-500 mr-2 mt-1">â€¢</span>
                                    Homozygous Familial Hypercholesterolemia (HoFH)
                                </li>
                                <li class="flex items-start">
                                    <span class="text-green-500 mr-2 mt-1">â€¢</span>
                                    Clinical ASCVD requiring additional LDL-C lowering
                                </li>
                                <li class="flex items-start">
                                    <span class="text-green-500 mr-2 mt-1">â€¢</span>
                                    CV risk reduction (MI, stroke, coronary revascularization)
                                </li>
                            </ul>
                        </div>
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Pediatric (Age 10+)</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li class="flex items-start">
                                    <span class="text-green-500 mr-2 mt-1">â€¢</span>
                                    HeFH or HoFH patients
                                </li>
                            </ul>
                            <div class="mt-4 p-3 bg-amber-50 dark:bg-amber-900/20 rounded-lg">
                                <p class="text-xs text-gray-700 dark:text-gray-300">
                                    <strong>Note:</strong> No dose adjustments required for renal/hepatic impairment, age, or weight
                                </p>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Dosing Information -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Dosing & Administration</h3>
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">140 mg</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Every 2 weeks</div>
                            <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">OR</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">420 mg monthly</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">12-26</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Annual injections</div>
                            <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">SC self-injection</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-purple-600 dark:text-purple-400">420 mg</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">HoFH dose</div>
                            <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Monthly, can increase</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">3 Sites</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-2">Injection locations</div>
                            <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Abdomen, thigh, arm</div>
                        </div>
                    </div>
                    <div class="mt-4">
                        <a href="https://www.repathainfo.com/healthcare-professional/dosing-administration" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View Full Prescribing Information â†’
                        </a>
                    </div>
                </div>
            </div>

            <!-- Mechanism Tab -->
            <div class="tab-content hidden" id="mechanism">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">PCSK9 Inhibition via Monoclonal Antibody</h3>
                    <div class="prose prose-sm max-w-none text-gray-600 dark:text-gray-400">
                        <p class="mb-4">
                            Repatha is a fully human monoclonal antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream. By inhibiting PCSK9's interaction with LDL receptors (LDL-R) on hepatocytes, it prevents receptor degradation.
                        </p>
                        <h4 class="font-medium text-gray-900 dark:text-white mb-3">Key Mechanisms:</h4>
                        <ul class="space-y-2 ml-4">
                            <li>â€¢ Increased LDL-R recycling on liver surface</li>
                            <li>â€¢ Enhanced clearance of LDL cholesterol from blood</li>
                            <li>â€¢ Substantial reductions in circulating LDL-C levels (50-70%)</li>
                            <li>â€¢ Rapid onset of effect (peak reduction within 1-2 weeks)</li>
                        </ul>
                    </div>
                    
                    <div class="mt-6 p-4 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20 rounded-lg border-l-4 border-indigo-500">
                        <p class="text-sm text-gray-700 dark:text-gray-300">
                            <strong>Key Differentiators:</strong> Unlike statins (which upregulate LDL-R expression) or inclisiran (which silences PCSK9 gene via siRNA), evolocumab acts post-translationally on circulating PCSK9, providing immediate effect without genetic modification.
                        </p>
                    </div>
                    
                    <div class="mt-4">
                        <a href="https://www.nature.com/articles/nrd.2016.112" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View Mechanism Research â†’
                        </a>
                    </div>
                </div>
            </div>

            <!-- Regulatory Timeline Tab -->
            <div class="tab-content hidden" id="regulatory">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">FDA Approval Timeline</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                        
                        <!-- Timeline items -->
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">AUGUST 27, 2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Initial FDA Approval</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Approved for HeFH, clinical ASCVD, and HoFH in adults/adolescents 13+. Second PCSK9 inhibitor approved in US.
                                </div>
                                <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-repatha-treat-certain-patients-high-cholesterol" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    FDA Announcement â†’
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">JULY 11, 2016</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Pushtronex System Approval</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    First single monthly injection device for 420 mg dosing (on-body infusor).
                                    <br><span class="text-amber-600 dark:text-amber-400">Note: Later discontinued in some markets</span>
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">DECEMBER 1, 2017</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">âœ“ CV Outcomes Indication</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    First PCSK9 inhibitor with outcomes-based indication for MI, stroke, and revascularization reduction.
                                    Based on FOURIER trial: 15% MACE reduction
                                </div>
                                <a href="https://www.amgen.com/newsroom/press-releases/2017/12/fda-approves-new-indication-for-use-of-repatha-evolocumab-to-prevent-heart-attack-stroke-and-coronary-revascularizations" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    Amgen Press Release â†’
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-purple-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-purple-600 dark:text-purple-400 mb-1">FEBRUARY 2021</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Pediatric Expansion</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Age limit lowered from 13+ to 10+ years for HeFH/HoFH patients.
                                    Based on HAUSER-RCT pediatric trial
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2024</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Label Updates</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Pregnancy/lactation data added from post-marketing reports.
                                    No new safety signals identified
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">EMA Approval Timeline</h3>
                    
                    <div class="relative pl-8">
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-blue-300 dark:via-blue-600 to-transparent"></div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">JULY 17, 2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">EMA Marketing Authorization</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Approved for primary hypercholesterolemia and mixed dyslipidemia. Broader initial indication than FDA.
                                </div>
                                <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/repatha" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    EMA Assessment â†’
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">MAY 16, 2018</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">CV Risk Reduction</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Expanded indication for MI, stroke, and PAD risk reduction based on FOURIER
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-blue-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-blue-600 dark:text-blue-400 mb-1">JUNE 28, 2024</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Latest Revision</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Updated SmPC, labeling, and package leaflet. Continuous monitoring via PBRERs.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div class="tab-content hidden" id="clinical">
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700 mb-8">
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Trial Name</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Phase</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">N</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Year</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Primary Endpoint</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Results</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Data</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">MENDEL</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-purple-100 dark:bg-purple-900/30 text-purple-800 dark:text-purple-400">Phase 2</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">406</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2013</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C at week 12</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">39-53% reduction</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01375751" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">GAUSS</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-purple-100 dark:bg-purple-900/30 text-purple-800 dark:text-purple-400">Phase 2</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">160</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2013</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C (statin-intolerant)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Similar efficacy</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01375764" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">LAPLACE-2</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">1,896</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2014</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C at weeks 10-12</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">63-75% reduction</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01763866" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">DESCARTES</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">901</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2015</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">% LDL-C at week 52</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">57% sustained</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01516879" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="bg-gradient-to-r from-green-50 to-emerald-50 dark:from-green-900/10 dark:to-emerald-900/10 hover:from-green-100 hover:to-emerald-100 dark:hover:from-green-900/20 dark:hover:to-emerald-900/20 transition-colors">
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">FOURIER</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">27,564</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">2017</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">CV death, MI, stroke, UA, revasc</td>
                                    <td class="px-6 py-4 text-sm font-bold text-gray-900 dark:text-white">HR 0.85 (15% RRR), p<0.001</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT01764633" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs font-bold">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">EBBINGHAUS</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">1,974</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2017</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Cognitive function</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">No impairment</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT02207634" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">FOURIER-OLE</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">6,635</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2022</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Long-term MACE (8.6 years)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">15% RRR sustained</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT02867813" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">VESALIUS-CV</td>
                                    <td class="px-6 py-4"><span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">Phase 3</span></td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">TBD</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2026</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Primary prevention MACE</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Pending</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT03872401" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View â†’</a>
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <!-- FOURIER Outcomes -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">FOURIER Trial - Detailed Outcomes</h3>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Primary Composite (MACE-5):</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ CV death, MI, stroke, UA hospitalization, coronary revascularization</li>
                                <li><strong class="text-gray-900 dark:text-white">â€¢ HR 0.85 (95% CI: 0.79-0.92)</strong></li>
                                <li><strong class="text-gray-900 dark:text-white">â€¢ 20% relative risk reduction, p<0.001</strong></li>
                            </ul>
                        </div>
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Key Secondary (MACE-3):</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ CV death, MI, stroke</li>
                                <li><strong class="text-gray-900 dark:text-white">â€¢ HR 0.80 (95% CI: 0.73-0.88)</strong></li>
                                <li><strong class="text-gray-900 dark:text-white">â€¢ 20% relative risk reduction</strong></li>
                            </ul>
                        </div>
                    </div>
                    <div class="mt-4 p-3 bg-amber-50 dark:bg-amber-900/20 rounded-lg">
                        <p class="text-xs text-gray-700 dark:text-gray-300">
                            <strong>Note on Mortality:</strong> No significant reduction in CV death (HR 1.05) or all-cause mortality (HR 1.04), likely due to short median follow-up of 2.2 years. Longer follow-up in FOURIER-OLE showed trend toward mortality benefit.
                        </p>
                    </div>
                    <div class="mt-4">
                        <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615664" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View FOURIER Publication (NEJM) â†’
                        </a>
                    </div>
                </div>

                <!-- Efficacy Chart -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Efficacy Outcomes</h3>
                    <div class="grid grid-cols-2 md:grid-cols-5 gap-6">
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-indigo-600 to-purple-600 bg-clip-text text-transparent">60%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">LDL-C Reduction<br>(Average)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-blue-600 to-cyan-600 bg-clip-text text-transparent">59%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">LDL-C Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-amber-600 to-orange-600 bg-clip-text text-transparent">30 mg/dL</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">Median LDL<br>Achieved</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-purple-600 to-pink-600 bg-clip-text text-transparent">20%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">MACE Reduction<br>(FOURIER)</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold bg-gradient-to-r from-green-600 to-emerald-600 bg-clip-text text-transparent">15%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mt-1">MACE Reduction<br>(Long-term)</div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div class="tab-content hidden" id="safety">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Safety Profile Overview</h3>
                    <div class="grid grid-cols-2 md:grid-cols-4 gap-6">
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">2.5M</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Patient-years</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">None</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Black Box Warnings</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">1.6%</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Discontinuation</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">8+ years</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400">Safety data</div>
                        </div>
                    </div>
                </div>

                <!-- Common AEs Grid -->
                <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="font-medium text-gray-900 dark:text-white mb-4">Most Common AEs</h4>
                        <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex justify-between">
                                <span>Nasopharyngitis</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">10.5%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Upper respiratory infection</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">9.3%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Influenza</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">7.5%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Back pain</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">6.2%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Injection site reactions</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">5.7%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Myalgia</span>
                                <span class="font-medium text-indigo-600 dark:text-indigo-400">5.4%</span>
                            </li>
                        </ul>
                    </div>

                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="font-medium text-gray-900 dark:text-white mb-4">Injection Site Reactions</h4>
                        <p class="text-sm text-gray-600 dark:text-gray-400 mb-3">Overall incidence: 5.7%</p>
                        <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex justify-between">
                                <span>Erythema</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">2.1%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Pain</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">1.8%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Bruising</span>
                                <span class="font-medium text-amber-600 dark:text-amber-400">1.2%</span>
                            </li>
                        </ul>
                        <p class="text-xs text-gray-500 dark:text-gray-500 mt-3">Generally mild and transient</p>
                    </div>

                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700">
                        <h4 class="font-medium text-gray-900 dark:text-white mb-4">Serious Adverse Events</h4>
                        <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                            <li class="flex justify-between">
                                <span>Overall SAEs</span>
                                <span class="font-medium text-green-600 dark:text-green-400">2.4%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Similar to placebo</span>
                                <span class="font-medium text-green-600 dark:text-green-400">2.3%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Hypersensitivity (rare)</span>
                                <span class="font-medium text-green-600 dark:text-green-400"><1%</span>
                            </li>
                            <li class="flex justify-between">
                                <span>Anaphylaxis</span>
                                <span class="font-medium text-green-600 dark:text-green-400">Very rare</span>
                            </li>
                        </ul>
                    </div>
                </div>

                <!-- Neurocognitive Safety -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">EBBINGHAUS Study - Neurocognitive Safety</h3>
                    <p class="text-gray-600 dark:text-gray-400 mb-4">
                        <strong>Primary Finding:</strong> No impact on cognitive function despite very low LDL-C levels
                    </p>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Cognitive Domains Tested:</h4>
                            <ul class="space-y-1 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Executive function</li>
                                <li>â€¢ Working memory</li>
                                <li>â€¢ Memory function</li>
                                <li>â€¢ Psychomotor speed</li>
                            </ul>
                        </div>
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Results:</h4>
                            <ul class="space-y-1 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Neurocognitive AEs: 1.6% vs 1.5% placebo</li>
                                <li>â€¢ No correlation with LDL level</li>
                                <li>â€¢ No difference in any cognitive domain</li>
                                <li>â€¢ 8+ year follow-up confirms safety</li>
                            </ul>
                        </div>
                    </div>
                    <div class="mt-4 p-3 bg-green-50 dark:bg-green-900/20 rounded-lg">
                        <p class="text-xs text-gray-700 dark:text-gray-300">
                            <strong>2024 Update:</strong> Study of 3,000+ patients with very low LDL (<20 mg/dL) showed no cognitive association over 5+ years. Meta-analyses confirm no neurocognitive risk.
                        </p>
                    </div>
                    <div class="mt-4">
                        <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1701131" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View EBBINGHAUS Publication â†’
                        </a>
                    </div>
                </div>

                <!-- Special Populations -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Special Populations & Monitoring</h3>
                    <div class="grid grid-cols-1 md:grid-cols-3 gap-6">
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700">
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3 flex items-center">
                                <span class="w-8 h-8 bg-gradient-to-r from-pink-500 to-rose-500 rounded-full flex items-center justify-center text-white text-sm mr-2">P</span>
                                Pregnancy & Lactation
                            </h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Insufficient evidence of fetal harm</li>
                                <li>â€¢ Discontinuation advised during pregnancy</li>
                                <li>â€¢ Limited data on breastfeeding</li>
                                <li>â€¢ 2024 label update with post-marketing data</li>
                            </ul>
                        </div>

                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700">
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3 flex items-center">
                                <span class="w-8 h-8 bg-gradient-to-r from-purple-500 to-indigo-500 rounded-full flex items-center justify-center text-white text-sm mr-2">I</span>
                                Immunogenicity
                            </h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Binding antibodies: 0.3%</li>
                                <li>â€¢ Neutralizing antibodies: Rare</li>
                                <li>â€¢ No impact on efficacy</li>
                                <li>â€¢ No cross-reactivity concerns</li>
                            </ul>
                        </div>

                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700">
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3 flex items-center">
                                <span class="w-8 h-8 bg-gradient-to-r from-amber-500 to-orange-500 rounded-full flex items-center justify-center text-white text-sm mr-2">D</span>
                                Diabetes Risk
                            </h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ New-onset diabetes: HR 1.05</li>
                                <li>â€¢ Not statistically significant</li>
                                <li>â€¢ Safe in T1D patients (2025 data)</li>
                                <li>â€¢ No glucose monitoring required</li>
                            </ul>
                        </div>
                    </div>
                    <div class="mt-4">
                        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125522s073lbl.pdf" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View Current FDA Label â†’
                        </a>
                    </div>
                </div>
            </div>

            <!-- Market Tab -->
            <div class="tab-content hidden" id="market">
                <!-- Pricing Evolution -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Pricing Evolution</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-green-300 dark:via-green-600 to-transparent"></div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-red-600 dark:text-red-400 mb-1">2015</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Launch Pricing</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block px-2 py-1 bg-red-100 dark:bg-red-900/30 text-red-800 dark:text-red-400 rounded mr-2">US: $14,000-14,600/year</span>
                                    <span class="inline-block px-2 py-1 bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400 rounded">EU: ~$6,780/year</span>
                                    <br><span class="mt-2 inline-block">Launch pricing led to significant payer pushback and strict prior authorizations</span>
                                </div>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">2018</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">60% Price Cut</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block px-2 py-1 bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400 rounded">$5,850/year</span>
                                    <br><span class="mt-2 inline-block">Post-FOURIER price reduction to improve access. Net price ~$4,500 with rebates</span>
                                </div>
                                <a href="https://www.amgen.com/newsroom/press-releases/2018/10/amgen-makes-repatha-evolocumab-available-in-the-us-at-a-60-percent-reduced-list-price" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    Amgen Announcement â†’
                                </a>
                            </div>
                        </div>

                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2020</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Access Challenges</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Only 3% of eligible high-risk ASCVD patients receiving therapy due to access barriers
                                </div>
                            </div>
                        </div>

                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2025</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Current Status</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    <span class="inline-block px-2 py-1 bg-indigo-100 dark:bg-indigo-900/30 text-indigo-800 dark:text-indigo-400 rounded">Annual sales: ~$1.3 billion</span>
                                    <br><span class="mt-2 inline-block">Sales plateaued. France pricing disputes. Biosimilars approaching in 2028</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Market Access Challenges -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Market Access Challenges</h3>
                    
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Prior Authorization Requirements:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ ~80% initial denial rate in US</li>
                                <li>â€¢ Must prove statin failure/intolerance</li>
                                <li>â€¢ LDL threshold requirements (>100-130 mg/dL)</li>
                                <li>â€¢ Documentation of CV risk factors</li>
                                <li>â€¢ Step therapy through other lipid agents</li>
                            </ul>
                        </div>
                        <div>
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">Payer Restrictions:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Express Scripts/UnitedHealth: Strict step therapy</li>
                                <li>â€¢ VA/CMS: Negotiated discounts, limited to severe</li>
                                <li>â€¢ NICE/HTA: Only for LDL >3.5-5 mmol/L in high-risk</li>
                                <li>â€¢ ICER assessment: >Â£30,000/QALY</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="mt-4 p-3 bg-amber-50 dark:bg-amber-900/20 rounded-lg">
                        <p class="text-xs text-gray-700 dark:text-gray-300">
                            <strong>Impact:</strong> Despite proven CV outcomes, restrictive coverage limits patient access. Real-world utilization remains <5% of eligible patients.
                        </p>
                    </div>
                    
                    <div class="mt-4">
                        <a href="https://www.amgenassistprogram.com/" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            Patient Assistance Programs â†’
                        </a>
                    </div>
                </div>

                <!-- Competitive Landscape -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Competitive Landscape</h3>
                    
                    <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-4 gap-4">
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">Praluent</div>
                            <div class="text-sm text-indigo-600 dark:text-indigo-400 mb-2">alirocumab</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">
                                PCSK9 mAb - Sanofi/Regeneron<br>
                                Similar efficacy, first to market
                            </div>
                            <a href="https://www.praluent.com" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                View â†’
                            </a>
                        </div>
                        
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">Leqvio</div>
                            <div class="text-sm text-indigo-600 dark:text-indigo-400 mb-2">inclisiran</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">
                                siRNA - Novartis<br>
                                Twice-yearly dosing advantage
                            </div>
                            <a href="https://www.leqvio.com" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                View â†’
                            </a>
                        </div>
                        
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">MK-0616</div>
                            <div class="text-sm text-amber-600 dark:text-amber-400 mb-2">Phase 3</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">
                                Oral PCSK9i - Merck<br>
                                Convenience of oral dosing
                            </div>
                            <a href="mk-0616.html" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                View Profile â†’
                            </a>
                        </div>
                        
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">Lerodalcibep</div>
                            <div class="text-sm text-amber-600 dark:text-amber-400 mb-2">Phase 3</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">
                                LIB Therapeutics<br>
                                Monthly dosing, Phase 3
                            </div>
                            <a href="https://www.libtherapeutics.com" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                View â†’
                            </a>
                        </div>
                    </div>
                </div>

                <!-- Future Outlook -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Patent Expiry & Biosimilars</h3>
                    
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-6">
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">US Market:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Exclusivity ends late 2027</li>
                                <li>â€¢ Biosimilars possible from 2028</li>
                                <li>â€¢ Expected 30-50% price reduction</li>
                            </ul>
                        </div>
                        <div class="p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <h4 class="font-medium text-gray-900 dark:text-white mb-3">EU Market:</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>â€¢ Similar timeline to US</li>
                                <li>â€¢ Earlier entries if patents challenged</li>
                                <li>â€¢ Pricing pressures from inclisiran deals</li>
                            </ul>
                        </div>
                    </div>
                    
                    <div class="p-4 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20 rounded-lg border-l-4 border-indigo-500">
                        <p class="text-sm text-gray-700 dark:text-gray-300">
                            <strong>Strategic Position:</strong> Despite competition from newer agents, Repatha's extensive outcomes data (FOURIER) and established safety profile ensure continued relevance. Biosimilar competition may actually improve access by reducing costs.
                        </p>
                    </div>
                    
                    <div class="mt-6 grid grid-cols-2 md:grid-cols-4 gap-4">
                        <div class="text-center">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">2027</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">US Patent Expiry</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">2028+</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">Biosimilar Entry</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">30-50%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">Price Reduction</div>
                        </div>
                        <div class="text-center">
                            <div class="text-2xl font-bold text-purple-600 dark:text-purple-400">10x</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">Potential Accessâ†‘</div>
                        </div>
                    </div>
                    
                    <div class="mt-4">
                        <a href="https://investors.amgen.com" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View Investor Relations â†’
                        </a>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- JavaScript -->
    <script>
        function toggleTheme() {
            document.body.classList.toggle('dark');
            localStorage.setItem('theme', document.body.classList.contains('dark') ? 'dark' : 'light');
        }

        // Load saved theme
        if (localStorage.getItem('theme') === 'dark' || (!localStorage.getItem('theme') && window.matchMedia('(prefers-color-scheme: dark)').matches)) {
            document.body.classList.add('dark');
        }

        function showTab(tabName, event) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => {
                tab.classList.add('hidden');
                tab.classList.remove('active');
            });
            
            // Update button styles
            const buttons = document.querySelectorAll('.tab-btn');
            buttons.forEach(btn => {
                btn.classList.remove('bg-indigo-600', 'text-white');
                btn.classList.add('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            });
            
            // Show selected tab
            document.getElementById(tabName).classList.remove('hidden');
            document.getElementById(tabName).classList.add('active');
            
            // Style active button
            event.target.classList.remove('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            event.target.classList.add('bg-indigo-600', 'text-white');
        }
    </script>
</body>
</html>